H.C. Wainwright raised the firm’s price target on Summit Therapeutics (SMMT) to $50 from $44 and keeps a Buy rating on the shares. The firm believes Akeso’s HARMONi-A study for ivonescimab validates the China data. The study shows that that ivonescimab beats Keytruda, the analyst tells investors in a research note. H.C. Wainwright believes it is time to own shares of Summit Therapeutics, which is the Akeso’s partner in the U.S.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics’ Ivonescimab: A Promising Competitor to Keytruda with Increased Approval Probability and Price Target
- Summit Therapeutics put volume heavy and directionally bearish
- Piper starts Summit Therapeutics with Neutral on high expectations
- Summit Therapeutics initiated with a Neutral at Piper Sandler
- Summit Therapeutics’ Promising Advancements in Cancer Treatment Drive Buy Rating